Kiniksa Pharmaceuticals, Ltd.·Healthcare

Kiniksa Pharmaceuticals continues to outperform, with Arcalyst net sales poised to surpass my previous bullish estimates. Arcalyst captured 18% of the recurrent pericarditis market by end-2025, with average therapy duration rising to three years and further upside from a new consumer awareness campaign. KPL-387, a next-generation IL-1 antibody, is set for phase 2 proof-of-concept data in H2 2026, offering improved economics and patient convenience compared to Arcalyst.

Enphase suffers from weaker U.S. demand, Fiverr jumps on Q1 earnings beat, and more

Its Arcalyst has been on the market for years, yet it posted strong sales growth in the period. More is to come, apparently, as management raised its net sales guidance for the drug.

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.

– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end – – Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today –
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.